NCT02874690View on ClinicalTrials.gov

Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 19, 2016

Primary Completion Date

August 3, 2017

Study Completion Date

August 3, 2017

Conditions
Autism Spectrum DisorderAttention Deficit Hyperactivity Disorder
Interventions
DRUG

Methylphenidate

single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg

DRUG

Placebo

Placebo pill identical in appearance to methylphenidate

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02874690 - Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD | Biotech Hunter | Biotech Hunter